Skip to main content

Ablative Radiotherapy Controls Resistant Non-Small Cell Lung Cancer in Clinical Trial

*December 2023*

Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is often diagnosed at an advanced stage. About half the time, it has already spread around the body and has reached stage 4. The standard treatment for most patients with metastatic NSCLC is systemic therapy (drugs that spread throughout the body) such as chemotherapytargeted therapy, or immunotherapy.

Systemic therapy, however, can become less effective against metastatic cancer over time. In some people, the treatment is still controlling the cancer in most places, but a small number of areas have begun to grow. This is called oligoprogressive disease. For these patients, the critical question becomes: Can radiation treatment stop cancer growth at this handful of sites so that systemic treatment can keep doing its job everywhere else?

Now a Memorial Sloan Kettering Cancer Center (MSK) team has shown that a highly focused radiation therapy called stereotactic body radiotherapy (SBRT) can keep oligoprogressive lung cancer under control more than four times longer than when patients receive standard care alone. Read more.